Company Filing History:
Years Active: 2017
Title: The Innovative Contributions of Mathilde Lopez-Grancha
Introduction
Mathilde Lopez-Grancha is a prominent inventor based in Massy, France. She has made significant strides in the field of pharmaceuticals, particularly in the treatment of neurodegenerative diseases. Her work focuses on developing innovative therapies that can potentially alter the course of Alzheimer's disease.
Latest Patents
Mathilde holds a patent for an H3 receptor antagonist aimed at treating Alzheimer's disease. This patent, which is titled "H3 receptor antagonist for use in the treatment of Alzheimer's disease," details methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in disease-modifying therapy. This invention is particularly relevant for addressing Alzheimer's disease, tauopathies, and other related neurodegenerative conditions. She has 1 patent to her name.
Career Highlights
Mathilde is currently employed at Sanofi, a leading global healthcare company. Her role involves extensive research and development in the pharmaceutical sector, where she applies her expertise to create effective treatments for complex diseases.
Collaborations
Throughout her career, Mathilde has collaborated with notable colleagues, including Pascal Barneoud and Veronique Blanchard-Bregeon. These partnerships have enhanced her research efforts and contributed to the advancement of innovative therapies.
Conclusion
Mathilde Lopez-Grancha's contributions to the field of pharmaceuticals, particularly in the treatment of Alzheimer's disease, highlight her role as a key innovator. Her work continues to inspire advancements in medical research and therapy development.